# Prior Successful Subsidiaries

AllMeD's track record: building and successfully exiting breakthrough medtech ventures

## Allium Medical

Urological & Gastrointestinal Stents

**Technology:** Proprietary fully-covered nitinol stents — primarily for urological applications (ureter, urethra, prostate) and biliary/GI indications

**Achievements:** CE Mark & FDA clearances. International commercial sales.

**Exit:** Successfully sold to **Dalhausen GmbH**

SUCCESSFUL EXIT ✓

## Gardia Medical

(now: ProCatid / UniGrd system)

**Technology:** WIRION embolic protection system — unique over-the-wire design avoids wire exchange and re-crossing the stenosis lesion

**Achievements:** FDA 510(k) clearance. CE Mark (EU). TGA approval (Australia). Successful commercialization.

**Exit:** IP and assets sold to **Cardiovascular Systems Inc (CSI)** — later acquired by Abbott Laboratories (April 2023)

SUCCESSFUL EXIT ✓

# Allium Medical

GI & Urological Nitinol Stents | Sold to Dalhausen GmbH, Germany

## Core Focus — Urological Stents

- Primarily urological stents: ureter, urethra, and prostatic applications
- Treatment of malignant & benign urological strictures and obstructions
- Also covers biliary and GI indications (duodenal, colorectal)
- Minimally invasive endoscopic deployment — no open surgery

## Technology

- Proprietary fully-covered nitinol stents — unique alloy properties
- Patented anti-migration design for long-term stable placement
- Custom-engineered delivery systems for urological anatomy
- Multiple stent configurations for different anatomical sites

## Regulatory & Commercial

- CE Mark approval (Europe)
- FDA 510(k) clearance (United States)
- International commercial sales — multiple markets
- Established global distribution and clinical network

## Exit — Dalhausen GmbH, Germany

- Acquired by Dalhausen, leading German surgical medtech company
- Dalhausen founded 1912; broad surgical products portfolio
- Validated AllMeD's Build-Develop-Exit medtech model
- Freed AllMeD capital to invest in cardiovascular pipeline

# Gardia Medical (now ProCatid Medical)

WIRION Embolic Protection Device | Sold to Cardiovascular Systems Inc. (CSI) → Abbott

## Clinical Problem Solved

- Emboli (clots, particles) released during catheterization cause stroke and MI
- Carotid artery stenting (CAS) carries high embolic risk to the brain
- Standard EPDs require wire exchange — adding complexity and stroke risk
- WIRION eliminated wire exchange: unique over-the-wire compatibility

## Key Technological Advantage

- Inserted OVER any standard guidewire — no need to replace the wire
- Avoids re-crossing the stenotic lesion: reduces procedural risk and time
- One-size filter fits arteries 3.5–6.0mm — universal compatibility
- Fully collapsible collection catheter captures all emboli on retrieval

## Regulatory Achievements

- FDA 510(k) clearance — USA (2015)
- CE Mark approval — European Union
- TGA approval — Australia & New Zealand (2016)
- Approved for carotid stenting indication with carotid stent

## Exit to CSI / Abbott

- IP, inventory, equipment sold to Cardiovascular Systems Inc. (CSI, 2019)
- CSI subsequently acquired by Abbott Laboratories (April 2023)
- ProCatid retained exclusive perpetual license for Carotid rights
- Exemplifies AllMeD's proven Build-Validate-Exit strategy